

PE/Dazzle™ 594 anti-human CD56 (NCAM) Recombinant

Catalog # / Size: 2594045 / 25 tests
2594050 / 100 tests

Clone: QA18A21

Isotype: Mouse IgG1, κ


Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with PE/Dazzle™

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)

Workshop Number: 594 under optimal conditions.

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with anti-human CD3 FITC and anti-human CD56 recombinant (clone QA18A21) PE/Dazzle™ 594 (left) or mouse IgG1, κ PE/Dazzle™ 594 isotype control (right).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

* PE/Dazzle™ 594 has a maximum excitation of 566 nm and a maximum emission of 610 nm.

Description: CD56 is a single transmembrane glycoprotein also known as NCAM (Neural Cell Adhesion Molecule), Leu-19, or NKH1. It is a member of the Ig superfamily. The 140 kD isoform is expressed on NK cells and NK-T cells. CD56 is also expressed in the brain (cerebellum and cortex) and at neuromuscular junctions. Certain large granular lymphocyte (LGL) leukemias, small-cell lung carcinomas, neuronal derived tumors, myelomas, and myeloid leukemias also express CD56. CD56 plays a role in homophilic and heterophilic adhesion via binding to itself or heparin sulfate.

**Antigen
References:**

1. Rosental B, et al. 2011. *J Immunol.* 187:5693. [PubMed](#)
2. Correia DV, et al. 2011. *Blood.* 118:992. [PubMed](#)
3. Schlecker E, et al. 2014. *Cancer Res.* 74:3429. [PubMed](#)
4. Snyder JM, et al. 2014. *PLoS One.* 9:e107257. [PubMed](#)
5. Siebert N, et al. 2014. *PLoS One.* 9:e107692. [PubMed](#)
6. Rider P, et al. 2015. *J Immunol.* 195:1705-12. [PubMed](#)
7. Davis ZB, et al. 2011. *J Vis Exp.* 49: 2668. [PubMed](#)
8. Robin JD, et al. 2015. *J Vis Exp.* 95: 52307. [PubMed](#)
9. Ames E, et al. 2015. *J Immunol.* 195: 4010-9. [PubMed](#)
10. Laroni A, et al. 2016. *J Autoimmun.* 72:8-18. [PubMed](#)
11. Pachnio A, et al. 2016. *PLoS Pathog.* 12:e1005832. [PubMed](#)
12. Wouters K, et al. 2017. *Sci Rep.* 7:42665. [PubMed](#)